all report title image

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Corticosteroids, Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published In : May 2024
  • Code : CMI2656
  • Pages :178
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Trends

Global chronic obstructive pulmonary disease (COPD) treatment market is estimated to be valued at USD 19.21 Bn in 2024 and is expected to reach USD 28.37 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Key Factors

To learn more about this report, request sample copy

Global chronic obstructive pulmonary disease (COPD) treatment market has been witnessing growth over the past few years due to huge  adoption of inhaled medications and bronchodilators for management of COPD symptoms. Furthermore, pipeline drugs with novel mechanisms of action are being evaluated for treatment of COPD, and this can expand therapeutic options. Many pharmaceutical companies are also investing heavily in development of combination therapies to ensure better treatment outcomes. However, high treatment costs can hamper the market growth. Increasing global disease burden of COPD supported by growing awareness regarding its management can boost demand for COPD therapeutics during the forecast period.

Increasing Research and development Activities by Key Market Players

Increasing research and development activities by key market players is expected to drive the market growth over the forecast period. For instance, on March 14, 2024, AstraZeneca, a global pharmaceutical company, announced that its triple combination inhaled therapy- Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) will be evaluated in a new phase 3 trial in patients with chronic obstructive pulmonary disease (COPD) and elevated cardiopulmonary risk.

/p>Increasing Awareness about Chronic Obstructive Pulmonary Disease (COPD)

Increasing adoption of inorganic growth strategies such as investments and fundings is expected to drive the market growth over the forecast period. For instance, in November 2021, according to the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote better understanding of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects millions across the US. Increasing awareness about chronic obstructive pulmonary disease (COPD) and its symptoms is important because early diagnosis and treatment can improve quality of life.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.